Reliance Group is now stepping into the healthcare industry. The Multinational conglomerate company will look to make inroads in genetic mapping.
According to reports, the Reliance group will launch a ₹12,000 ($145) genome sequencing test. The product will be developed by Strand Life Sciences Pvt. Reliance acquired the Bengaluru-based firm in 2021 and now owns about 80% of it.
The genome sequencing test can reveal a person's predisposition to cancers, cardiac diseases, and neurodegenerative diseases. It can also identify inherited genetic disorders.
Even though ₹12,000 may sound like a lot, the test is said to be 86% cheaper than other tests available in India. The project will offer a fairly affordable personal gene mapping to Indians.
The project will also create biological data which will help policymakers to take measures that would aid disease prevention and drug development. It would also help in targeted treatments and generating early interventions.
The project will also be marked as the entry of the Reliance group in the world of data which they have often called the "new oil."
(Input from various media sources)
